|Bid||39.35 x 3000|
|Ask||39.55 x 2900|
|Day's Range||39.16 - 39.54|
|52 Week Range||33.26 - 42.68|
|Beta (5Y Monthly)||0.40|
|PE Ratio (TTM)||13.57|
|Earnings Date||Feb. 01, 2017 - Feb. 06, 2017|
|Forward Dividend & Yield||2.17 (5.41%)|
|Ex-Dividend Date||May 20, 2021|
|1y Target Est||48.04|
Dr. Elizabeth Clayborne, Adjunct Assistant Professor of Emergency Medicine at the University of Maryland School of Medicine and Emergency Physician at UM Capital Region Medical Center, joins Yahoo Finance to discuss the latest in the coronavirus pandemic.
While Pfizer and BioNTech's Comirnaty and Moderna's COVID-19 vaccine have dominated the discussion surrounding COVID-19 vaccines, Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine has also positioned itself for blockbuster status. For instance, Johnson & Johnson's COVID-19 vaccine is expected to bring in $2.5 billion for the pharma stock this year alone. Let's discuss the clinical results of Johnson & Johnson's RSV vaccine candidate to date, as well as its sales potential to understand why this could be Johnson & Johnson's next blockbuster vaccine.
Johnson & Johnson (NYSE: JNJ) recently announced positive results from a phase 2 study of its RSV vaccine candidate. In this Motley Fool Live video recorded on Oct. 6, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not J&J set a high bar for Pfizer (NYSE: PFE) and GlaxoSmithKline (NYSE: GSK) to top.